Human-Centered Drug Discovery: The world’s drug discovery machinery has a tragic paradox. Academic labs, pharmaceutical companies, and biotechs have better tools than ever before: supercomputers, genomic sequencers, PCR. Despite these incredible technologies, the drug discovery success rate is lower now than it was in the 1970s. There are two reasons for this: First, the era of ‘big data’ has not been translated into effective drugs, as was initially expected. Second, current approaches for target discovery rely far too much on inbred animal models (mice, rats, etc.), and drugs that work wonders in these animals. These pre-clinical studies fail far too often, then too late in clinical trials, making the process wasteful and imprecise. To overcome these challenges, iNetMed’s two Centers, The Center for Precision Computational System Network (PreCSN) and HUMANOID Center of Research Excellence (CoRE) are working collaboratively to provide an end-to-end new paradigm and platform for drug discovery that begins with target identification (at PreCSN) and ends with target validation in human disease models (at HUMANOID).